Safety and feasibility of autologous adipose-derived stromal vascular fraction in the treatment of keloids: a phase one randomized controlled pilot trial.
Mbiine R., Kayiira A., Wayengera M., Guyton MI., Kiwanuka N., Alenyo R.
Clinical Trial with a reported sample of 8 on Scar, published in Am J Stem Cells (2023) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Am J Stem Cells (2023)
- Country
- United States
- Reported sample size
- 8
- Source database
- PubMed
- PMID
- 37215278
- PMCID
- PMC10195396
- DOI
- 10.21203/rs.3.rs-940210/v1
- NCT
- NCT04553159
- Citations
- 5
Abstract (original English)
Abstract Autologous adipose-derived stromal vascular fraction (SVF) is described as a therapeutic alternative in keloid treatment. However, most conclusions are based on observational with the majority conducted in high-income countries and yet the highest-burden of keloids is in Low-and middle-income countries (LMICs). In order to explore the therapeutic benefits of SVF in keloids, the safety and feasibility of their use in LMICs need to be evaluated. Methods: In this phase 1 randomized controlled pilot clinical trial conducted in the Plastic Surgery Unit of Kirruddu National Referral Hospital Kampala, 8 patients were assigned 1:1 ratio into either SVF or Triamcinolone Acetonide (TAC) arms. In the SVF arm, a median (IQR) number of stromal cell infiltration of 2.7x10 6 (11x10 6 ) was administered while the controls received 10mg/ml TAC in a ratio of 1:1 TAC into keloid volume. Primary end-points were adverse events development based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 tool and Feasibility assessment based on ≥70% recruitment feasibility and ≥80% interventional feasibility rates. Results: Participant mean age was 27.9 (±6.5) years with a female predilection of 5(63%). Overall, no adverse events were reported in the SVF arm while an ulceration in a single patient in the TAC arm which was a grade II adverse event was reported. Recruitment feasibility
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level AMeta-analysisPubMed
Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis.
Meta-analysis with a reported sample of 323 on Scar, published in Eur J Obstet Gynecol Reprod Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 323
Eur J Obstet Gynecol Reprod Biol - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol - Level AMeta-analysisPubMed
Efficacy and safety of autologous cell-based therapies for atrophic acne scar treatment: an updated systematic review and meta-analysis with in-depth methodological and clinical insights.
Meta-analysis with a reported sample of 500 on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 500
Front Cell Dev Biol - Level ASystematic ReviewEurope PMC
Comparative Efficacy and Safety of Fractional CO<sub>2</sub> Laser and Gold Microneedling Radiofrequency for Atrophic Acne Scars: A Systematic Review
Systematic Review on Chronic Wound, Scar, published in Skin Res Technol (2026) — summary generated from the PubMed abstract.
- 2026
Skin Res Technol - Level AMeta-analysisPubMed
Role of exosome therapy in reconstructive surgery: a review.
Meta-analysis on Chronic Wound, Scar, Immune Modulation, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Med (Lausanne)1 citations